

***Mycoplasma orale* 2, Strain CH 20247**

Catalog No. NR-3853

This reagent is the property of the U.S. Government.

Lot (NIAID) Number: M-714-012-084

For research use only. Not for human use.

Contributor:

National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH)

Manufacturer and Contract:

Baltimore Biological Laboratory, PH-43-67-1468

Product Description:

Reagent: Seed

Classification: *Mycoplasmataceae*

Species: *Mycoplasma orale* 2 (*M. orale* 2)

Type Strain: CH 20247

NIAID Class: Research Reference Reagent

Donor: Laboratory of Infectious Diseases, NIAID

Donor Passage History (# of passages): 3x cloned

Producer Passage History (# of passages): 3

Note: BEI Resources was asked to distribute this bacterial preparation from NIAID's historical repository. Historical characterization information is shown below in the **Functional Activity and Purity sections.**

Material Provided:

Each vial contains approximately 0.5 mL of *M. orale* 2 grown in Complete *Mycoplasma* broth (Medium E, see Appendix I for media composition).

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Storage:

NR-3853 was packaged in vials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

Potency:

Titer: 5.7 × 10⁷ colony-forming units per mL, in 11 days on medium A (see Appendix I for media composition).

Date of Last Test: December 1970

Purity:

Homologous Antiserum Testing: Demonstrated inhibition when tested against a specific homologous antiserum. No evidence of heterotypic mycoplasma.

Heterologous Antiserum Testing:

Disc Inhibition and Fluorescent Antibody: Negative when tested against *M. arthritis*, *M. gallinarum*, *M. gallisepticum*, *A. granularum*, *M. hominis*, *M. hyorhinis*, *A. laidlawii* A, *A. laidlawii* B, *M. orale* 1, *M. pneumoniae*, *M. pulmonis*, *M. salivarium* and *M. spumans*.

Separate Disc Inhibition: Negative when tested against *M. arthritis*, *M. canis*, *M. fermentans*, and *M. iners*.

Separate Fluorescent Antibody: Negative when tested against *M. primum*, *M. lipophilum*, and *M. arginini*.

Bacterial Sterility: Negative

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Mycoplasma orale* 2, Strain CH 20247, NR-3853."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its

derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Taylor-Robinson, D. and R. M. Chanock. "Characterization of a Newly Identified Mycoplasma from the Human Oropharynx." *Am. J. Epidemiol.* 81 (1964): 180-191. PubMed: 14261024.
2. Freundt, E. A., et al. "Proposal of *Mycoplasma buccale* nom. nov. and *M. faucium* nom. nov. for *Mycoplasma*

orale Types 2 and 3." *International J. Syst. Bacteriol.* 24 (1974): 252-255.

3. NIAID Catalog of Research Reagents 1978-1980. U.S. Department of Health, Education, and Welfare Publication No. (NIH) 78-899. Ed. S. Cunningham. NIAID/NIH, Bethesda, MD, USA.

ATCC® is a trademark of the American Type Culture Collection.



Appendix I: Media³

Complete *Mycoplasma* broth (Medium E)

| | |
|------------------------------|---------------|
| <i>Mycoplasma</i> broth base | 78% |
| Normal horse serum | 20% |
| Yeast extract dialysate | 2% |
| Potassium penicillin G | 1000 units/mL |

Medium A

| | |
|---------------------|---------------|
| BBL. PPLO broth | 7% |
| Yeast extract (25%) | 1% |
| Unheated mule serum | 2% |
| Penicillin | 1000 units/mL |
| Thallium acetate | 1:2000 |